Jennifer Rosen
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 9 | 2022 | 380 | 2.550 |
Why?
| | Thyroidectomy | 11 | 2022 | 97 | 1.990 |
Why?
| | Thyroid Nodule | 6 | 2021 | 67 | 1.720 |
Why?
| | General Surgery | 3 | 2026 | 217 | 1.550 |
Why?
| | Thyroxine | 2 | 2022 | 67 | 1.320 |
Why?
| | Endocrine Surgical Procedures | 2 | 2026 | 3 | 1.140 |
Why?
| | Complementary Therapies | 3 | 2014 | 93 | 1.090 |
Why?
| | Parathyroidectomy | 2 | 2024 | 10 | 1.010 |
Why?
| | Hyperparathyroidism, Primary | 2 | 2024 | 7 | 1.010 |
Why?
| | Time-to-Treatment | 2 | 2026 | 257 | 0.970 |
Why?
| | Surgeons | 2 | 2025 | 351 | 0.790 |
Why?
| | Goals | 1 | 2025 | 187 | 0.790 |
Why?
| | Mentors | 1 | 2025 | 217 | 0.760 |
Why?
| | Hormone Replacement Therapy | 2 | 2022 | 107 | 0.720 |
Why?
| | Mentoring | 1 | 2025 | 166 | 0.720 |
Why?
| | Referral and Consultation | 2 | 2026 | 881 | 0.660 |
Why?
| | Thyroid Gland | 3 | 2019 | 93 | 0.640 |
Why?
| | Vulnerable Populations | 2 | 2022 | 178 | 0.590 |
Why?
| | Hypothyroidism | 1 | 2019 | 68 | 0.580 |
Why?
| | Sociological Factors | 1 | 2016 | 6 | 0.480 |
Why?
| | Social Determinants of Health | 2 | 2022 | 317 | 0.480 |
Why?
| | Spectrum Analysis | 2 | 2013 | 85 | 0.460 |
Why?
| | Delivery of Health Care | 2 | 2022 | 947 | 0.450 |
Why?
| | Internship and Residency | 1 | 2026 | 1281 | 0.450 |
Why?
| | Carcinoma, Medullary | 1 | 2015 | 16 | 0.430 |
Why?
| | Safety-net Providers | 1 | 2016 | 133 | 0.430 |
Why?
| | Emergency Medical Services | 1 | 2022 | 680 | 0.420 |
Why?
| | Overweight | 1 | 2019 | 614 | 0.420 |
Why?
| | Kelp | 1 | 2014 | 2 | 0.410 |
Why?
| | Phytotherapy | 1 | 2014 | 74 | 0.390 |
Why?
| | Graves Disease | 2 | 2013 | 32 | 0.390 |
Why?
| | Cytological Techniques | 1 | 2013 | 25 | 0.390 |
Why?
| | Benchmarking | 1 | 2014 | 193 | 0.380 |
Why?
| | Robotics | 1 | 2014 | 89 | 0.380 |
Why?
| | Integrative Medicine | 1 | 2013 | 17 | 0.380 |
Why?
| | Thyroid Diseases | 1 | 2013 | 45 | 0.370 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2014 | 196 | 0.370 |
Why?
| | Retrospective Studies | 13 | 2026 | 17438 | 0.370 |
Why?
| | Humans | 39 | 2026 | 146342 | 0.350 |
Why?
| | Middle Aged | 16 | 2026 | 36619 | 0.340 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 7 | 0.330 |
Why?
| | Carcinoma, Papillary | 1 | 2010 | 83 | 0.310 |
Why?
| | Female | 23 | 2026 | 79499 | 0.310 |
Why?
| | Pilot Projects | 2 | 2026 | 1888 | 0.310 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2009 | 13 | 0.310 |
Why?
| | Intussusception | 1 | 2009 | 24 | 0.300 |
Why?
| | Male | 21 | 2026 | 73396 | 0.300 |
Why?
| | Iodine Radioisotopes | 3 | 2022 | 139 | 0.300 |
Why?
| | Colonic Diseases | 1 | 2009 | 39 | 0.300 |
Why?
| | Neoplasms | 2 | 2016 | 2954 | 0.300 |
Why?
| | Laparoscopy | 1 | 2014 | 487 | 0.300 |
Why?
| | Parathyroid Neoplasms | 2 | 2008 | 12 | 0.290 |
Why?
| | Adult | 15 | 2026 | 41087 | 0.290 |
Why?
| | Health Services Accessibility | 2 | 2017 | 1107 | 0.280 |
Why?
| | Lymphoma, B-Cell | 1 | 2009 | 150 | 0.270 |
Why?
| | Aged | 12 | 2026 | 26432 | 0.270 |
Why?
| | Case-Control Studies | 2 | 2026 | 3647 | 0.250 |
Why?
| | Patient Acceptance of Health Care | 1 | 2013 | 881 | 0.240 |
Why?
| | Obesity | 1 | 2019 | 3131 | 0.230 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6073 | 0.230 |
Why?
| | Parathyroid Glands | 1 | 2005 | 11 | 0.220 |
Why?
| | Quality of Health Care | 3 | 2015 | 702 | 0.220 |
Why?
| | United States | 9 | 2026 | 16136 | 0.210 |
Why?
| | Hospitalization | 4 | 2018 | 2475 | 0.200 |
Why?
| | Universities | 1 | 2026 | 451 | 0.200 |
Why?
| | Health Care Surveys | 3 | 2015 | 541 | 0.200 |
Why?
| | Lymphatic Metastasis | 2 | 2022 | 335 | 0.190 |
Why?
| | Adenoma | 1 | 2005 | 210 | 0.190 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2023 | 74 | 0.190 |
Why?
| | Nursing Staff, Hospital | 2 | 2015 | 146 | 0.180 |
Why?
| | Socioeconomic Factors | 3 | 2017 | 1327 | 0.180 |
Why?
| | Program Evaluation | 2 | 2025 | 952 | 0.180 |
Why?
| | Data Accuracy | 1 | 2022 | 64 | 0.180 |
Why?
| | Scattering, Radiation | 2 | 2013 | 98 | 0.180 |
Why?
| | Postoperative Complications | 3 | 2022 | 3034 | 0.170 |
Why?
| | Disinfection | 1 | 2023 | 131 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2015 | 41 | 0.170 |
Why?
| | Genomics | 1 | 2006 | 853 | 0.170 |
Why?
| | Housing | 1 | 2022 | 142 | 0.160 |
Why?
| | Combined Modality Therapy | 2 | 2014 | 1271 | 0.160 |
Why?
| | Multivariate Analysis | 2 | 2022 | 1543 | 0.160 |
Why?
| | Endocrinology | 1 | 2021 | 77 | 0.160 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1792 | 0.160 |
Why?
| | Hashimoto Disease | 1 | 2020 | 10 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1998 | 0.150 |
Why?
| | Healthcare Disparities | 2 | 2017 | 733 | 0.150 |
Why?
| | Lymph Nodes | 1 | 2022 | 511 | 0.140 |
Why?
| | Patient Reported Outcome Measures | 1 | 2023 | 516 | 0.140 |
Why?
| | Physician-Patient Relations | 2 | 2014 | 597 | 0.140 |
Why?
| | Neck Dissection | 1 | 2018 | 17 | 0.140 |
Why?
| | Health Services Research | 3 | 2017 | 390 | 0.130 |
Why?
| | Prospective Studies | 2 | 2025 | 8123 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2025 | 3017 | 0.130 |
Why?
| | Professional Practice | 2 | 2015 | 58 | 0.130 |
Why?
| | Young Adult | 6 | 2018 | 14330 | 0.120 |
Why?
| | Machine Learning | 1 | 2022 | 594 | 0.120 |
Why?
| | Hospital Mortality | 2 | 2018 | 1051 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2014 | 11821 | 0.120 |
Why?
| | Boston | 1 | 2016 | 90 | 0.120 |
Why?
| | Minority Groups | 1 | 2018 | 286 | 0.120 |
Why?
| | Personnel Administration, Hospital | 1 | 2015 | 3 | 0.120 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2016 | 80 | 0.110 |
Why?
| | Clinical Competence | 1 | 2024 | 1272 | 0.110 |
Why?
| | Hospitals, Urban | 1 | 2016 | 140 | 0.110 |
Why?
| | Age Factors | 2 | 2019 | 3347 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2018 | 322 | 0.110 |
Why?
| | Surgical Instruments | 1 | 2014 | 51 | 0.100 |
Why?
| | Thymus Hyperplasia | 1 | 2013 | 1 | 0.100 |
Why?
| | Cohort Studies | 3 | 2020 | 6077 | 0.100 |
Why?
| | Germ-Line Mutation | 1 | 2015 | 180 | 0.100 |
Why?
| | Lymph Node Excision | 1 | 2015 | 174 | 0.100 |
Why?
| | Myocardial Infarction | 2 | 2018 | 1215 | 0.100 |
Why?
| | Weight Loss | 1 | 2019 | 858 | 0.100 |
Why?
| | History, 21st Century | 1 | 2014 | 224 | 0.100 |
Why?
| | Comprehensive Health Care | 1 | 2013 | 24 | 0.100 |
Why?
| | Hand Strength | 1 | 2014 | 149 | 0.100 |
Why?
| | Cadaver | 1 | 2014 | 304 | 0.100 |
Why?
| | Comparative Effectiveness Research | 1 | 2014 | 171 | 0.090 |
Why?
| | History, 20th Century | 1 | 2014 | 330 | 0.090 |
Why?
| | Hand | 1 | 2014 | 157 | 0.090 |
Why?
| | Algorithms | 2 | 2013 | 1849 | 0.090 |
Why?
| | Poverty | 1 | 2016 | 530 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 966 | 0.090 |
Why?
| | Risk | 1 | 2014 | 920 | 0.090 |
Why?
| | Genetic Testing | 1 | 2015 | 492 | 0.090 |
Why?
| | Workplace | 1 | 2014 | 268 | 0.090 |
Why?
| | Medical Oncology | 1 | 2014 | 345 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 1160 | 0.080 |
Why?
| | Postoperative Care | 1 | 2013 | 301 | 0.080 |
Why?
| | Chronic Disease | 1 | 2017 | 1827 | 0.080 |
Why?
| | Body Mass Index | 1 | 2019 | 2458 | 0.080 |
Why?
| | Hospitals | 1 | 2015 | 738 | 0.080 |
Why?
| | Light | 1 | 2013 | 401 | 0.080 |
Why?
| | Preoperative Care | 1 | 2013 | 396 | 0.080 |
Why?
| | Self Care | 1 | 2013 | 396 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2019 | 8391 | 0.080 |
Why?
| | Principal Component Analysis | 1 | 2010 | 192 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 3200 | 0.080 |
Why?
| | Antithyroid Agents | 1 | 2009 | 12 | 0.070 |
Why?
| | Etoposide | 1 | 2009 | 169 | 0.070 |
Why?
| | Decision Trees | 1 | 2009 | 76 | 0.070 |
Why?
| | Vincristine | 1 | 2009 | 148 | 0.070 |
Why?
| | Cyclophosphamide | 1 | 2009 | 275 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 1 | 2009 | 122 | 0.070 |
Why?
| | Self Report | 1 | 2013 | 870 | 0.070 |
Why?
| | Internet | 1 | 2013 | 660 | 0.070 |
Why?
| | Prednisone | 1 | 2009 | 229 | 0.070 |
Why?
| | Sacrococcygeal Region | 1 | 2008 | 6 | 0.070 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2008 | 2 | 0.070 |
Why?
| | Databases, Factual | 1 | 2014 | 1493 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2013 | 770 | 0.070 |
Why?
| | Diagnostic Tests, Routine | 1 | 2009 | 109 | 0.070 |
Why?
| | Genes, Homeobox | 1 | 2008 | 50 | 0.070 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2008 | 64 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2113 | 0.060 |
Why?
| | Risk Factors | 1 | 2022 | 10921 | 0.060 |
Why?
| | Patient Care Team | 1 | 2013 | 701 | 0.060 |
Why?
| | Adolescent | 4 | 2018 | 22557 | 0.060 |
Why?
| | Doxorubicin | 1 | 2009 | 416 | 0.060 |
Why?
| | Goiter, Nodular | 1 | 2006 | 2 | 0.060 |
Why?
| | Sodium Pertechnetate Tc 99m | 1 | 2006 | 4 | 0.060 |
Why?
| | Teratoma | 1 | 2008 | 121 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1219 | 0.060 |
Why?
| | Disease Progression | 1 | 2015 | 2867 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 79 | 0.060 |
Why?
| | Medical History Taking | 1 | 2006 | 117 | 0.060 |
Why?
| | Lung Diseases | 1 | 2013 | 787 | 0.060 |
Why?
| | Thyrotropin | 1 | 2006 | 120 | 0.060 |
Why?
| | Biopsy, Needle | 1 | 2006 | 183 | 0.060 |
Why?
| | Diabetic Angiopathies | 2 | 2018 | 265 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 640 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2010 | 1998 | 0.060 |
Why?
| | Prognosis | 1 | 2015 | 4351 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 3 | 2013 | 2786 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2008 | 616 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5899 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1408 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2005 | 496 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1707 | 0.050 |
Why?
| | Medicare | 1 | 2009 | 920 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 752 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 614 | 0.050 |
Why?
| | Ultrasonography | 1 | 2006 | 788 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1503 | 0.050 |
Why?
| | Kidney Failure, Chronic | 2 | 2018 | 589 | 0.040 |
Why?
| | Up-Regulation | 1 | 2005 | 841 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2023 | 376 | 0.040 |
Why?
| | Reoperation | 1 | 2022 | 645 | 0.040 |
Why?
| | Prophylactic Surgical Procedures | 1 | 2018 | 7 | 0.030 |
Why?
| | Skin | 1 | 2023 | 701 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 399 | 0.030 |
Why?
| | Propensity Score | 1 | 2019 | 376 | 0.030 |
Why?
| | Acculturation | 1 | 2017 | 55 | 0.030 |
Why?
| | Insurance Claim Review | 1 | 2017 | 87 | 0.030 |
Why?
| | California | 1 | 2018 | 475 | 0.030 |
Why?
| | Mutation | 1 | 2008 | 4093 | 0.030 |
Why?
| | American Hospital Association | 1 | 2015 | 9 | 0.030 |
Why?
| | Hospital Bed Capacity | 1 | 2015 | 28 | 0.030 |
Why?
| | Organizational Culture | 1 | 2015 | 159 | 0.030 |
Why?
| | Role | 1 | 2014 | 28 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1038 | 0.030 |
Why?
| | Social Environment | 1 | 2015 | 246 | 0.020 |
Why?
| | Hospital Administration | 1 | 2014 | 26 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 368 | 0.020 |
Why?
| | Quality Improvement | 1 | 2022 | 1354 | 0.020 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 133 | 0.020 |
Why?
| | Length of Stay | 1 | 2019 | 1358 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2126 | 0.020 |
Why?
| | Cough | 1 | 2013 | 123 | 0.020 |
Why?
| | Environment | 1 | 2014 | 299 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3416 | 0.020 |
Why?
| | Leadership | 1 | 2015 | 414 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2861 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2013 | 330 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1075 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1272 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3712 | 0.020 |
Why?
| | Stroke | 1 | 2018 | 1287 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2013 | 711 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 974 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2008 | 1432 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2008 | 2791 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2488 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 3926 | 0.010 |
Why?
| | Pregnancy | 1 | 2008 | 7230 | 0.010 |
Why?
|
|
Rosen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|